|
Indian Pediatr 2015;52: 813 |
|
Predictors of Survival in Children with
Methymalonic Acidemia with Homocystinuria
|
Naveen Sankhyan and *Pratibha Singhi
Pediatric Neurology Unit, Department of Pediatrics,
Advance Pediatric Center,
PGIMER, Chandigarh, India.
*Email:
[email protected]
|
We read with interest the recent report by Qiliang, et al. [1] on
the outcome of 45 children diagnosed with combined methymalonic academia
(MMA) and homocystinemia. The authors report a 40% mortality in their
cohort. Apart from mortality, it would be important to know the degree
and pattern of neuromorbidity in the survivors. Combined MMA and
homocystinemia is a potentially treatable inborn error of metabolism,
and high mortality and possibly high morbidity in the reported cohort
need a careful evaluation. The high mortality in the reported cohort can
partly be explained by the inadequate parenteral B 12
replacement given to the patients. Highlighting the importance of
meticulous long-term treatment, we wish to point out certain important
aspects of management of children with combined MMA and homocystinemia.
The critical component of the treatment of combined
MMA and homocystinemia is parentral B 12.
This therapy has to be given in the adequate doses daily and lifelong.
Hydroxyl-cobalamine injections are the only form of B12
proven to be beneficial in patients with this disorder. It is
recommended that hydroxyl-cobalamine be given daily intravenously,
subcutaneously or intramuscularly. The recommended dose of parenteral
hydroxyl-cobalamine is 0.3 mg/kg/ day, once a day. The suggested
targeted plasma B-12 levels are ³1,000,000
pg/mL [2]. Previous reports have shown that the progression of
complications in patients with combined MMA and homocystinemia arise in
part due to inadequate hydroxyl-cobalamine. There are several reports of
marked clinical and neurological deterioration in patients weaned from
daily to less frequent dosing [3,4]. Hence, it is essential for all
involved in the care of affected individuals to ensure daily
administration of the injection. The monitoring parameters include serum
MMA and total homocystine levels and normalization of plasma methionine
and hematological parameters. The other co-factors recommended for use
include oral Betaine (250 mg/kg/day in 3 divided doses), oral Folinic
acid (5-15 mg/day in 2-3 Divided doses), and oral Levocarnitine (50-100
mg/kg/day in 3 divided doses).
References
1. Qiliang L, Wenqi S, Quan W, Xinying Y, Jiuwei L,
Qiang S, et al. Predictors of survival in children with
methymalonic acidemia with homocystinuria in Beijing, China: A
prospective cohort study. Indian Pediatr. 2015;52:119-24.
2. Carrillo-Carrasco N, Chandler RJ, Venditti CP.
Combined methylmalonic academia and homocystinuria, cblC type. I.
Clinical presentations, diagnosis and management. J Inherit Metab Dis.
2012;35:91-102.
3. Roze E, Gervais D, Demeret S, Ogier de Baulny H,
Zittoun J, Benoist JF, et al. Neuropsychiatric disturbances in
presumed late-onset cobalamin C disease. Arch Neurol. 2003;60:1457-62.
4. Augoustides-Savvopoulou P, Mylonas I, Sewell AC,
Rosenblatt DS. Reversible dementia in an adolescent with cblC disease:
clinical heterogeneity within the same family. J Inherit Metab Dis.
1999;22:756-8.
Editor’s notes: The corresponding author of the original paper
referred to in this correspondence did not provide any response.
|
|
|
|